MAINZ BIOMED B.V. EO 1 news, videos and press releases
For more news please use our advanced search feature.
MAINZ BIOMED B.V. EO 1 - More news...
MAINZ BIOMED B.V. EO 1 - More news...
- Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
- EQS-News: Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
- Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
- Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
- EQS-News: Mainz Biomed Announces Stock Split
- Mainz Biomed Announces Stock Split
- EQS-News: Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
- Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
- EQS-News: Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
- Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
- Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
- EQS-News: Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
- EQS-News: Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
- Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
- EQS-News: Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
- Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
- EQS-News: Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
- Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
- EQS-News: Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
- Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
- EQS-News: Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
- Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
- EQS-News: Mainz Biomed Provides Half Year 2024 Corporate Update
- Mainz Biomed Provides Half Year 2024 Corporate Update
- EQS-News: Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
- Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
- Mainz Biomed Reports Results of 2024 Annual General Meeting
- EQS-News: Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
- Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
- Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
